Company / Operating Cash Flow
NovaBay Pharmaceuticals, Inc. Operating Cash Flow History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$5.2M
FY2024
5-year range
-$9.2M / -$4.3M
FY2020-FY2024
Trend
-21.6%
vs FY2023
Sector context
#76 of 214
Health Care
What the data says
At -$5M, NovaBay Pharmaceuticals, Inc.'s operating cash flow ranks #76 of 214 in the Health Care sector. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$19M in FY2015 to -$4M in FY2023.
Based on SEC 10-K filings.
-$5M in FY2024.
Improved from -$7M to -$5M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#76 of 214 in Health CareTop 36% of 214This company -$5.2M Sector average $663.6M
▼
-100.8% below sector average
Key checks
Key Insights
- In FY2024, operating cash flow decreased 21.6% year-over-year.
- Ranks #76 out of 214 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2023.
- Lowest operating cash flow in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$5.2M | -21.6% |
| FY2023 | -$4.3M | +36.0% |
| FY2022 | -$6.7M | +27.6% |
| FY2021 | -$9.2M | -94.7% |
| FY2020 | -$4.7M | +40.5% |
| FY2019 | -$7.9M | -42.4% |
| FY2018 | -$5.6M | +11.2% |
| FY2017 | -$6.3M | +46.2% |
| FY2016 | -$11.7M | +37.2% |
| FY2015 | -$18.6M | -23.3% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026